Jacob Bell
Senior Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1643 articles by Jacob Bell
-
Shares of psychedelics biotech nearly double on depression data
Feb. 3, 2025 -
A new, non-opioid pain drug is here. Getting it to patients could be agony.
Jan. 31, 2025 -
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
Jan. 30, 2025 -
Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world
Jan. 16, 2025 -
At JPM, Biogen CEO tries to take down the deal temperature
Jan. 15, 2025 -
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Jan. 13, 2025 -
J&J to buy psychiatric drug developer Intra-Cellular for $14.6B
Jan. 13, 2025 -
ALS drugs from Denali, Calico come up short, marking setback for Healey trial
Jan. 7, 2025 -
5 FDA decisions to watch in the first quarter of 2025
Jan. 6, 2025 -
Neumora plummets on depression drug data
Jan. 2, 2025 -
Roche sticks with Parkinson’s drug despite second study failure
Dec. 19, 2024 -
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Dec. 19, 2024 -
A Vertex partner — and potential rival — secures $100M to develop non-opioid pain drugs
Dec. 18, 2024 -
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
Dec. 13, 2024 -
UniQure shares soar on chance of speedy approval for Huntington’s therapy
Dec. 10, 2024 -
GSK taps a startup for shot at Alzheimer’s drug
Dec. 5, 2024 -
Dewpoint, Mitsubishi partner on ALS drug in deal worth up to $480M
Dec. 4, 2024 -
Novartis wagers billions of dollars on PTC Huntington’s drug
Dec. 2, 2024 -
How Intra-Cellular surprised Wall Street by breaking character
Nov. 27, 2024 -
Roche to buy cell therapy developer Poseida for $1B
Nov. 26, 2024 -
Alector turns to layoffs as Alzheimer’s drug fails
Nov. 26, 2024 -
Novartis wagers more than $1B on gene therapies for the nervous system
Nov. 21, 2024 -
Sage’s string of research failures continues
Nov. 20, 2024 -
How a Biogen drug set the stage for a new biotech targeting ALS
Nov. 15, 2024 -
Eisai wins over European regulators on Alzheimer’s drug Leqembi
Nov. 14, 2024